Abstract
Amyloid vaccine therapy aims to reduce amyloid burden in AD brain and to protect neuronal cell death. Although AN1792 vaccine has been confirmed to reduce amyloid, the therapy has caused meningoencephalitis. Currently, the safer vaccine, Bapineuzumab, is on the phase III clinical trials. There are two injection ways, antigen or antibodies, for decreasing amyloid. Monitoring vasogenic edema by brain MRI is the key to continue Amyloid vaccine therapy. It is one of the problems that there might be some AD patients with severe BPSD to monitor brain MRI in the future. Carrying Apolipoprotein E4 would be the risk factor for vasogenic edema. Other biological biomarkers evaluating the risk for vasogenic edema should be investigated.
